128833-96-5

Basic information

• Product Name: 2,6-Dichloro-DL-Phenylalanine
• Synonyms: 2,6-Dichloro-DL-Phenylalanine;H-DL-Phe(2,6-Cl2)-OH;2,6-Dichloro-DL-Phenylalanine hydrochloride
• CAS NO: 128833-96-5
• Molecular Formula: C₉H₉Cl₂NO₂*ClH
• Molecular Weight: 234.07926
• Mol File: 128833-96-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2,6-Dichloro-DL-Phenylalanine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dichloro-DL-Phenylalanine(128833-96-5)
• EPA Substance Registry System: 2,6-Dichloro-DL-Phenylalanine(128833-96-5)

Safety Data

• Hazardous Substances Data: 128833-96-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dichloro-DL-Phenylalanine is used as a building block in the synthesis of various drugs, contributing to the development of new therapeutic agents due to its unique structural properties.
Used in Agrochemical Industry:
It is used as a key ingredient in the production of herbicides, where its chemical structure aids in the formulation of effective weed control agents.
Used in Research and Development:
2,6-Dichloro-DL-Phenylalanine is employed as a research tool for its potential therapeutic properties, allowing scientists to explore new avenues in medicine and treatment options.
Used in Biochemical Studies:
It is utilized for its ability to modify the structure of proteins, serving as a valuable asset in understanding protein functions and interactions within biological systems.

Upstream product

• 20443-98-5 2,6-Dichlorobenzyl bromide 
• 1068-90-2 2-acetylaminomalonic acid diethyl ester 
• 115491-80-0 2-acetylamino-2-(2,6-dichlorobenzyl)malonic acid diethyl ester 

Downstream Products

• 856571-36-3 3-(2,6-dichlorophenyl)-2-{2-[(1H-indole-2-carbonyl)amino]benzoylamino}propionic acid ethyl ester 

Relevant articles and documents

Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"

In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.

Synthesis and antitumor activity of platinum(II) complexes containing substituted ethylenediamine ligands

The synthesis of substituted ethylenediamines, their reactions with K2PtCl4 to give the dichloroplatinum(II) complexes, and the exchange of the chloro ligands for other leaving groups are described.The new compounds have been tested as antitumor agents both in vitro using the hormone independent human mammary carcinoma cell line MDA-MB 231 as well as in vivo using the lymphocytic P388 leukemia of the CD2F1-mouse.In the P388 test, 53 of the 55 tested complexes fulfill the minimum activity of 125percent T/C required for a substance to be active.